CJC-1295 with DAC vs. CJC-1295 without DAC: Clinical & Research Differences with a Focus on GH Pulsatility
CJC-1295 is a growth hormoneโreleasing hormone (GHRH) analog. Attaching a Drug-Affinity Complex (DAC) enables
albumin binding and markedly prolongs half-life. In contrast, the non-DAC (short-acting) formโcommonly referred to as
Mod GRF(1-29)โhas a brief plasma life and produces transient, pulse-like GH elevations. These pharmacokinetic
distinctions shape whether GH output is sustained or pulsatile, with implications for physiologic signaling.
Product page for laboratory research:
CJC-1295 (Research Use Only)
.
Head-to-Head Comparison
| Feature | CJC-1295 with DAC | CJC-1295 without DAC (Mod GRF(1-29)) |
|---|---|---|
| Design | Albumin-binding via DAC โ long-acting GHRH analog | Short-acting GHRH(1-29) analog without albumin binding |
| Half-life / Exposure | Prolonged exposure (days) with sustained GH/IGF-1 rise in humans1 | Minutes; brief spikes in plasma โ transient GH pulses |
| GH Secretion Pattern | Elevates basal GH and augments pulses, trending toward a more tonic profile under continuous exposure1 | Primarily pulsatile bursts when dosed intermittently, aligning with physiologic ultradian GH rhythms2 |
| Physiologic Relevance | Useful for sustained stimulation; may blunt relative pulse amplitude depending on background somatostatin tone | Better preserves timing-dependent physiology and receptor recovery windows described for normal GH neuroendocrine control2 |
| Downstream Readouts | Clear increases in circulating IGF-1 over days to weeks in early clinical studies1 | Short-window GH/IGF-1 excursions; magnitude depends on dose timing and co-secretagogues |
Why Pulsatility Matters
Human GH physiology is governed by alternating hypothalamic GHRH and somatostatin signals that create
~8โ12 pulses per 24 h. Pulses are thought to optimize receptor signaling, hepatic IGF-1 generation, and downstream metabolic effects.
Short-acting GHRH analogs can be timed to reinforce natural peaks, whereas long-acting exposure tends to raise mean GH/IGF-1
more steadily but may flatten the relative pulse amplitude in some settings.2
Implications for Study Design (Research-Only)
- Endpoints: 12โ24 h GH profiling (deconvolution), IGF-1, and pulse metrics (frequency, mass, interpulse interval).
- Dosing Logic: Non-DAC analogs enable time-of-day strategies to probe physiologic alignment; DAC enables exposure-response studies over days.
- Context: Background somatostatin tone, sleep status, caloric state, and co-secretagogues (e.g., ghrelin mimetics) can materially alter outcomes.
Maintain sourcing consistency for comparability:
CJC-1295 โ research page.
References (max 2)
- Teichman SL, etย al. Prolonged stimulation of GH and IGF-1 by CJC-1295, a long-acting GHRH analog.
J Clin Endocrinol Metab. 2006;91(3):799-805. (Demonstrates albumin binding, extended half-life, and sustained IGF-1 response in humans.) - Veldhuis JD, Bowers CY. Human GH pulsatility: regulation and clinical implications.
Endocrine Reviews. 2003;24(6): 782-793. (Overview of physiologic pulsatile GH control and the roles of GHRH and somatostatin.)
Compliance & Research-Only Notice
Pure Tested Peptides supplies compounds strictly for laboratory research use only.
All information above is for educational and scientific discussion. Products are not medicines or drugs,
are not intended for human consumption, and have not been evaluated or approved by the FDA to diagnose, treat,
cure, or prevent any disease.
